Tenderwize
Zurück zur Suche

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2028 · 762 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

20/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

20 / 100

Komplexität

30 / 100

Risikofaktoren

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Aug 2028
  • Non-exclusive discount agreements for Oralair(R) (ATC V01AA02) under § 130a Abs. 8 SGB V
  • Supply of pharmaceutical product including parallel and re-imports
Vollständige Zusammenfassung anzeigen

This is a non-exclusive pharmaceutical discount agreement under an Open-House model for the drug Oralair(R) (ATC V01AA02), organized by AOK PLUS for Saxony and Thuringia. The agreement is not a formal public procurement but a voluntary transparency notice. Any qualified pharmaceutical entrepreneur can join by submitting participation documents via the DTVP portal. The first submission deadline is August 5, 2026, with periodic deadlines thereafter. The agreement ends on August 31, 2028. No estimated value, guaranteed volumes, or award criteria are provided. The process is open but subject to confidentiality and early termination if exclusive agreements are concluded.

Risiken

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Eligibility

  • Must submit declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit Russia sanctions declaration (Eigenerklärung Russlandsanktionen)

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

This lot covers the conclusion of non-exclusive discount agreements for the pharmaceutical product Oralair(R) (ATC V01AA02), including parallel and re-imports. The contract is under an Open-House model, with rolling submission deadlines. The agreement ends on August 31, 2028. No minimum volume or exclusivity is guaranteed.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Aug 2026 - Aug 2028

Kategorie

Pharmaceutical products

Frist

Deadline Aug 31, 2028

Vergabedetails

Veröffentlichungsdatum
09 Jul 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
477144-2026

Dokumente (1)

Ähnliche Ausschreibungen